Sky Gold and Diamonds Limited Compliance Confirmation for Quarter Ended March 2026

Sky Gold and Diamonds Limited has officially confirmed the completion of depository participant verification for the quarter ended 31st March 2026. The company, in collaboration with its registrar, MUFG Intime India Private Limited, has verified that all security certificates received for dematerialization have been processed, mutilated, and cancelled. This process ensures that all shareholder records are accurately updated within the prescribed timelines, maintaining transparency in the company’s equity and depository management processes.

Quarterly Depository Compliance

Sky Gold and Diamonds Limited has successfully completed its statutory depository compliance for the fourth quarter of the fiscal year, ending 31st March 2026. This confirmation aligns with standard market practices to ensure that all equity dematerialization requests are handled with full verification and regulatory adherence.

Verification and Processing Standards

The company’s registrar and transfer agent, MUFG Intime India Private Limited, has confirmed that all security certificates received from participants during the quarter have undergone rigorous validation. Following the verification process, these certificates were formally mutilated and cancelled. This critical step prevents the circulation of outdated physical certificates and safeguards the integrity of the company’s electronic shareholding records.

Shareholder Registry Updates

As part of the dematerialization cycle, the names of the respective depositories have been successfully substituted in the company’s Register of Members. This update confirms that all processed securities are now accurately reflected as held by the registered owners within the specified electronic system, providing assurance to investors regarding the accuracy and timeliness of their shareholding status.

Source: BSE

Previous Article

Pearl Global Industries Compliance Confirmation for Quarter Ended March 31, 2026

Next Article

Orchid Pharma Whole Time Director to Participate in Investor Roadshow